Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 9, 2020

Harbour BioMed, Mount Sinai to develop Covid-19 therapies

Biopharmaceutical company Harbour BioMed has partnered with academic medical system Mount Sinai Health to develop new biotherapies for Covid-19, and also cancer.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Biopharmaceutical company Harbour BioMed has partnered with academic medical system Mount Sinai Health to develop biotherapies for Covid-19 and cancer.

The partners entered into a multi-year, multifaceted agreement, which will focus on fully human antibodies.

As part of the collaboration, the partners will leverage the H2L2 Harbour Mice platform to produce monoclonal antibodies targeting the novel coronavirus that causes Covid-19.

The monoclonal antibodies could be used in a manner to treat those exposed to the virus, or prophylactically to protect individuals at a high risk of exposure, such as healthcare workers, said Harbour BioMed.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

These antibodies will be designed to prevent the spread of the virus by inhibiting infection of cells.

Mount Sinai Icahn School of Medicine  Center for Therapeutic Antibody Development director Thomas Moran said: “We are pleased to be able to collaborate with HBM at this time and leverage our experience in therapeutic antibody generation as well as the viral expertise of the Microbiology department with the unique human antibody-producing mice from Harbour.”

Mount Sinai will contribute via its expertise in translational medical research.

Harbour BioMed founder, chairman and CEO Jingsong Wang said: “This is a unique collaboration that will give HBM access to Mount Sinai’s innovative research-driven from its clinical practices.

“The agreement demonstrates HBM’s commitment to develop novel medicines and foster fast-track innovative research.  We will push the boundaries of science and the development of new medicines that will ultimately translate into better treatments for patients.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU